Critical

Opioid-induced respiratory depression (naloxone)

Reverse opioid narcosis, titrate to breathing · Perioperative & Anaesthesia
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Opioid-induced respiratory depression presents with reduced respiratory rate, sedation and hypoxia, and can progress to apnoea and arrest. Naloxone is titrated to restore adequate ventilation WITHOUT fully reversing analgesia or precipitating acute withdrawal; its short half-life mandates monitoring for re-sedation.

Red flags

  • Respiratory rate <8/min or apnoea
  • Falling SpO2 despite oxygen
  • Pinpoint pupils with reducing consciousness
  • Re-sedation after initial naloxone response (short half-life)
  • Concurrent long-acting/sustained-release or transdermal opioid

Assessment

Differential diagnosis

  • Other sedatives (benzodiazepines, gabapentinoids) contributing
  • Hypercapnic respiratory failure (COPD, OSA)
  • Residual neuromuscular blockade
  • Hypoglycaemia, stroke or other causes of reduced consciousness
  • Hypoxia from pulmonary/airway cause
  • Sepsis or metabolic cause

Investigations

  • Assess ABC, respiratory rate, sedation score (e.g. AVPU/Pasero scale), SpO2 and pupils
  • Arterial/venous blood gas for CO2 and oxygenation
  • Review opioid doses, routes and other sedatives administered
  • Capnography where available
  • Blood glucose and basic observations
  • Consider residual neuromuscular blockade if recent anaesthesia

Management

  • Recognise early: increasing sedation with falling respiratory rate (<8-10/min) and/or desaturation
  • Call for help and open the airway; apply high-flow oxygen and support ventilation (bag-mask) if inadequate
  • Stop all opioid infusions/PCA and remove transdermal opioid patches
  • Give titrated IV naloxone in small increments to restore adequate breathing while preserving analgesia
  • Repeat naloxone every 2-3 minutes until respiratory rate and consciousness are acceptable
  • If no IV access, give naloxone IM/intranasal
  • Because naloxone is shorter-acting than most opioids, monitor closely for re-sedation and consider a naloxone infusion for long-acting/sustained-release opioids
  • Identify contributing sedatives and renal impairment (accumulation)
  • Continue close monitoring (SpO2, RR, sedation) in an appropriate setting until stable
  • Review the analgesic plan, document the event and report as a patient-safety incident

Drugs & doses

Naloxone 40-100 microgram IV every 2-3 min titrated to adequate ventilation (dilute 400 microgram in 10 mL = 40 microgram/mL)
In full arrest/no IV access: Naloxone 400 microgram IM or 400 microgram-2 mg intranasal
Naloxone infusion: ~60% of the effective waking dose per hour for recurrent/long-acting opioid toxicity
Maintain oxygen and ventilatory support throughout

Disposition

Escalate to critical care outreach/anaesthetics; monitor in HDU/high-observation area until reliably stable off naloxone, and revise the analgesic regimen.

Complications & pitfalls

  • Respiratory arrest and hypoxic brain injury
  • Acute withdrawal, agitation, hypertension and pulmonary oedema from over-reversal
  • Loss of analgesia and severe pain/sympathetic surge
  • Arrhythmia
  • Re-narcotisation after naloxone wears off

Exam pearls

  • Titrate naloxone to BREATHING, not to full wakefulness - over-reversal causes pain, withdrawal and dangerous sympathetic surges
  • Naloxone's short duration means re-sedation is common - monitor and consider an infusion, especially with modified-release or transdermal opioids
  • Sedation score rises before SpO2 falls on supplemental oxygen - watch sedation and RR, not SpO2 alone
  • Renal impairment causes active morphine metabolites to accumulate - prefer oxycodone/fentanyl and lower doses
  • Always look for co-sedatives (benzodiazepines, gabapentinoids) compounding the picture

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.